Ablexis gets $12M Series A; AVI shares boosted by promising muscle data;

 @FierceBiotech: Researcher: New vaccine "could eliminate breast cancer." Story | Follow @FierceBiotech

 @JohnCFierce: Bit dated, but this New York Times piece on dangers in the lab seems a bit inflated with anecdotes and seriously short on facts. Report | Follow @JohnCFierce

> Who's vulnerable to Amgen's new bone drug? Story

> San Francisco-based Ablexis has raised $12 million in a Series A. Third Rock Ventures led the round with Pfizer Venture Investments joining in. The money will be used to continue advancing Ablexis' AlivaMab Mouse platform for the discovery of therapeutic antibodies. Ablexis release

> Shares of AVI BioPharma (AVII) were buoyed this morning by reports that its experimental drug for a genetic muscle-wasting disease produced promising data in a Phase Ib/II study. Report

> Pfizer told 500 scientists in New London to be ready to move soon. Report

> The FDA will provide a priority review of Eisai's breast cancer drug eribulin. Report

> Follica reports that it has raised $7.5 million in new financing. Report

> Onconova Therapeutics has gained $10 million in backing from the Leukemia & Lymphoma Society for new cancer drug development work. Release

> Oramed Pharmaceuticals subsidiary Oramed Ltd. has entered into a joint venture agreement with Laser Detect Systems for the establishment of a new company to be called Entera Bio Ltd. Oramed release

And Finally... Maryland Gov. Martin O'Malley is proposing a new tax credit plan for technology and the life sciences industry that could be worth up to $100 million. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.